Memorial Sloan Kettering Cancer Center in New York is re-examining conflicts of interest after articles by ProPublica and The New York Times highlighted the relationships between its staff and health care companies.
Dr. José Baselga, the hospital’s chief medical officer, stepped down days after a report by ProPublica and the New York Times that he failed to disclose millions of dollars in payments from the health care and drug industry in research articles.
A policy review follows months of turmoil at the cancer center, which pledged an overhaul, including new rules on public disclosure and limits on outside profits.
The cancer center will now bar top officials from sitting on outside boards of for-profit companies, and is conducting a wide-scale review of other policies.
AstraZeneca has hired Dr. José Baselga, the former chief medical officer at Memorial Sloan Kettering, to lead its cancer research unit.
One of the nation’s top cancer hospitals has grappled with how to bring breakthrough treatments to market while remaining true to its mission.
Dr. José Baselga, the former chief medical officer of Memorial Sloan Kettering Cancer Center, was asked to resign after he failed to disclose corporate ties in dozens of scientific articles.
The hospital’s chief medical officer resigned last month after failing to disclose company ties in medical journals. Now, Memorial Sloan Kettering researchers, including chief executive Dr. Craig B. Thompson, are updating their own conflict-of-interest disclosures.
Under scrutiny for the hospital’s industry ties and compensation, Dr. Craig B. Thompson stepped down from two company boards.
The executive told Memorial Sloan Kettering staff that the hospital did not do enough to limit the industry conflicts of its chief medical officer, who has resigned.
A vice president at Memorial Sloan Kettering received a stake of nearly $1.4 million in a biotech company for representing the hospital on its board. He will give back his stake as the cancer center grapples with questions about conflicts of interest.
The change highlights the challenges facing Memorial Sloan Kettering, one of the nation’s most prestigious cancer centers, amid a widening crisis.
A for-profit venture with exclusive rights to use the cancer center’s vast archive of tissue slides has generated concerns among pathologists at the hospital, as well as experts in nonprofit law and corporate governance.
The move comes after ProPublica and The New York Times reported that one of its top executives failed to report payments from drug and health care companies in dozens of medical journal articles.
A senior official at Memorial Sloan Kettering Cancer Center has received millions of dollars in payments from companies that are involved in medical research. His omissions expose how weakly conflict-of-interest rules are enforced by journals.